Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
N C Turner, E Alarcón, A C Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2022
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast Cancer
John F R Robertson, Abigail Evans, Stephan Henschen, et al.
NPJ Breast Cancer
|
April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M Hyman, Lillian M Smyth, Mark T A Donoghue, et al.
Cancer Research
|
September 19, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Mandy Lawson, Natalie Cureton, Susana Ros, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
N C Turner, E Alarcón, A C Armstrong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2022
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2020
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>-</sup> Primary Breast Cancer
John F R Robertson, Abigail Evans, Stephan Henschen, et al.
NPJ Breast Cancer
|
April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2020
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> <sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers
Udai Banerji, Emma J Dean, J Alejandro Pérez-Fidalgo, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M Hyman, Lillian M Smyth, Mark T A Donoghue, et al.
Cancer Research
|
September 19, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Mandy Lawson, Natalie Cureton, Susana Ros, et al.
Page
of 3